CJC-1295 does not put muscle on you directly. It raises IGF-1, and IGF-1 is the signal that tells muscle tissue to grow. The gain that follows is modest and measured in months, not the steroid-like result the marketing implies.
CJC-1295 raises growth hormone and IGF-1 for days at a time, which is why it gets marketed for muscle. A single subcutaneous dose produced dose-dependent increases in mean plasma GH of 2 to 10-fold for 6 days or more, and increases in IGF-1 of 1.5 to 3-fold for 9 to 11 days [1]. What that sustained elevation does for lean mass is a narrower story than the marketing suggests.
- CJC-1295 with Drug Affinity Complex has an estimated half-life of 5.8 to 8.1 days, so one injection stimulates the GH axis for a week [1]
- Higher IGF-1 drives skeletal muscle protein synthesis, which is the real mechanism behind any lean-mass effect [6]
- Controlled human data on GH-axis elevation shows lean body mass rises while measured strength and exercise capacity do not [4]
- CJC-1295 is not an anabolic steroid. It works upstream through the pituitary and does not act on androgen receptors
- No controlled trial has measured muscle gain from CJC-1295 specifically. The lean-mass case is inferred from IGF-1 kinetics and older GHRH data [5]
- CJC-1295 is on the WADA prohibited list under growth hormone releasing factors, which disqualifies tested athletes [8]
What CJC-1295 Does to the GH Axis
CJC-1295 is a modified fragment of GHRH bound to albumin. It is a tetrasubstituted form of hGRF(1-29) that bioconjugates to serum albumin, and that binding is what produces the multi-day duration [3]. It turns a peptide that would clear in minutes into one that stimulates the pituitary for a week.
Sustained does not mean a constant flood of hormone. A study built to test the pulsatility concern found that one week after dosing, the frequency and magnitude of GH secretory pulses were unaltered, while basal GH rose 7.5-fold, mean GH rose 46%, and IGF-1 rose 45% [2]. The pituitary keeps pulsing on its own schedule. The baseline it pulses from is higher.
That distinction matters for muscle. The IGF-1 elevation is real and lasts for days, but it sits on top of a system still governed by somatostatin feedback, not a fixed exogenous dose you control from outside.
One practical point the marketing blurs: the week-long duration belongs to the version bound to albumin through Drug Affinity Complex. The unbound modified GRF(1-29) that some vendors also label CJC-1295 clears within hours and behaves more like sermorelin [3]. If the muscle pitch rests on multi-day IGF-1 elevation, it applies only to the DAC form.
What Higher IGF-1 Does for Lean Mass
IGF-1 is the signal that links the GH axis to muscle tissue. It regulates skeletal muscle hypertrophy by activating satellite cells and the downstream protein-synthesis pathways [6]. Raise IGF-1 and you raise the input to that system. That is the honest mechanistic basis for the muscle claim.
The complication is what controlled data shows when you actually elevate GH in healthy adults. A systematic review of growth hormone in athletes found lean body mass increased, but a share of that gain reflected fluid retention, and neither strength nor exercise capacity improved measurably [4]. Bigger on a scale is not the same as stronger in the gym.
The closest long-term GHRH-analog data tells the same restrained story. Nightly GHRH(1-29) analog for 16 weeks in adults aged 55 to 71 increased lean body mass in men, with no significant change in fat mass over that window [5]. Real lean-mass movement, modest in size, and measured over months rather than weeks.
Two people on the same dose will not get the same result. Baseline IGF-1, training status, sleep, and protein intake move the outcome more than small dose changes do. The peptide raises the ceiling on lean-mass signaling. Whether you reach it depends on the inputs you control.
Why CJC-1295 Is Not a Steroid
This is the most common misunderstanding, and the mechanism settles it. Anabolic steroids are androgen-receptor agonists that push protein synthesis directly in muscle regardless of feedback. CJC-1295 does none of that. It stimulates the pituitary to release its own GH, which the liver converts to IGF-1 [1][3].
The practical differences follow from the mechanism. Somatostatin feedback limits how far the axis can be driven, the pituitary is not suppressed, and there is no androgenic load on the prostate, hair, or lipids. The ceiling is lower and so is the risk profile. The trade-off is that the effect on muscle is smaller and slower than what androgens produce.
| Property | CJC-1295 | Anabolic steroid |
|---|---|---|
| Primary target | Pituitary GHRH receptor [3] | Androgen receptor |
| Active molecule | Your own GH, then IGF-1 [1] | Synthetic androgen |
| Feedback control | Limited by somatostatin | None |
| Lean-mass effect | Modest, IGF-1 mediated [5][6] | Large, direct |
| Anti-doping status | Prohibited, GH releasing factors [8] | Prohibited |
The Ipamorelin Stack
CJC-1295 is rarely run alone for body composition. The common protocol pairs it with ipamorelin, a selective growth hormone secretagogue that adds a second release signal without raising cortisol or prolactin [7]. The GHRH analog and the secretagogue act on different receptors, and the combination produces a larger GH pulse than either alone.
What the stack does not have is a controlled human trial measuring muscle or body composition. The rationale is sound and the individual pieces are studied, but the specific combination for lean mass rests on mechanism and user reports, not a randomized endpoint. Treat confident before-and-after claims accordingly.
Who This Actually Suits
CJC-1295 fits a narrow group: adults with documented low or low-normal IGF-1 who want sustained axis support and prefer less frequent dosing than nightly sermorelin. It is not a shortcut to a physique, and anyone expecting steroid-like gains will be disappointed.
If muscle is the only goal, resistance training and protein intake do more than any peptide. CJC-1295 supports recovery and slow lean-mass gain in people whose GH axis has declined with age. It does not replace the work.
Whatever you decide, a baseline IGF-1 before starting and a retest at 90 days are non-negotiable. Any program that prescribes without them is skipping the one measurement that tells you whether the protocol is doing anything.
CJC-1295 and ipamorelin only make sense with a baseline IGF-1 and physician-reviewed titration. SystemLabs sources peptides from licensed U.S. pharmacies and pairs you with a clinician, so the GH axis gets measured rather than guessed at.
Frequently Asked Questions
Does CJC-1295 build muscle?
CJC-1295 raises IGF-1, the signal that drives skeletal muscle protein synthesis [6], so it supports lean-mass gain rather than causing it outright. Controlled data on GH-axis elevation shows lean body mass rises while measured strength does not [4], and no trial has quantified muscle gain from CJC-1295 specifically. Expect recovery and body-composition support over months, not a rapid physique change.
Is CJC-1295 a steroid?
No. Anabolic steroids act directly on androgen receptors in muscle. CJC-1295 stimulates the pituitary to release its own growth hormone, which the liver converts to IGF-1 [1][3]. It carries no androgenic load and the axis stays under somatostatin feedback, which is why the muscle effect is smaller and the risk profile is different.
How long until CJC-1295 affects body composition?
IGF-1 rises within days of the first dose and stays elevated for over a week per injection [1]. Visible body-composition change runs on a slower clock. The nearest long-term GHRH-analog data measured lean-mass gain in men over 16 weeks [5], so judge results at 3 to 6 months with an IGF-1 retest, not in the first few weeks.
Is CJC-1295 better than sermorelin for muscle?
The difference is duration, not a different muscle mechanism. Both raise GH and IGF-1 through the same GHRH receptor. CJC-1295 with DAC lasts 5.8 to 8.1 days per dose [1], while sermorelin clears in minutes and is dosed nightly. Neither has a controlled trial measuring muscle gain, so choose based on dosing preference and provider quality, not a promised size difference.
Why is CJC-1295 stacked with ipamorelin?
Ipamorelin is a selective growth hormone secretagogue that triggers GH release through a different receptor than CJC-1295 and does not raise cortisol or prolactin [7]. Pairing a GHRH analog with a secretagogue produces a larger combined GH pulse than either alone. The stack is mechanistically sound, though no randomized trial has measured its effect on muscle.
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/
- Systematic review: the effects of growth hormone on athletic performance Annals of Internal Medicine, 2008. PMID: 18347346. https://pubmed.ncbi.nlm.nih.gov/18347346/
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy Cells, 2020. PMID: 32858949. https://pubmed.ncbi.nlm.nih.gov/32858949/
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
